- Home
- Publications
- Publication Search
- Publication Details
Title
Precision oncology: neither a silver bullet nor a dream
Authors
Keywords
-
Journal
PHARMACOGENOMICS
Volume 18, Issue 16, Pages 1525-1539
Publisher
Future Medicine Ltd
Online
2017-10-24
DOI
10.2217/pgs-2017-0094
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Current treatment options and investigational drugs for Waldenstrom’s Macroglobulinemia
- (2017) Maria Gavriatopoulou et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis
- (2016) Aksana K. Jones et al. AAPS Journal
- Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q
- (2016) Ekaterina Balaian et al. ANNALS OF HEMATOLOGY
- Cobimetinib
- (2016) Jessie Signorelli et al. ANNALS OF PHARMACOTHERAPY
- The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib
- (2016) W. T. Parker et al. BLOOD
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G
- (2016) Kohei Shitara et al. CANCER SCIENCE
- Clinical trial designs incorporating predictive biomarkers
- (2016) Lindsay A. Renfro et al. CANCER TREATMENT REVIEWS
- FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib
- (2016) E. Larkins et al. CLINICAL CANCER RESEARCH
- Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer
- (2016) Emily Han-Chung Hsiue et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- PARP inhibition and gynecologic malignancies: A review of current literature and on-going trials
- (2016) S.M. Crafton et al. GYNECOLOGIC ONCOLOGY
- Activity and safety of ceritinib in patients with ALK -rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
- (2016) Dong-Wan Kim et al. LANCET ONCOLOGY
- Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
- (2016) Susan O'Brien et al. LANCET ONCOLOGY
- Alectinib in ALK -positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
- (2016) Alice T Shaw et al. LANCET ONCOLOGY
- Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer
- (2016) Federico Cappuzzo et al. LUNG CANCER
- therascreen ® EGFR RGQ PCR Kit: A Companion Diagnostic for Afatinib and Gefitinib in Non-Small Cell Lung Cancer
- (2016) Yahiya Y. Syed Molecular Diagnosis & Therapy
- Perspective: The precision-oncology illusion
- (2016) Vinay Prasad NATURE
- Limits to Personalized Cancer Medicine
- (2016) Ian F. Tannock et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ponatinib in the therapy of chronic myeloid leukemia
- (2016) Marc Poch Martell et al. Expert Review of Hematology
- NCI-MATCH Trial Draws Strong Interest
- (2016) Cancer Discovery
- Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay
- (2016) Maria Schwaederle et al. Oncotarget
- Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics
- (2015) M. A. Dimopoulos et al. ANNALS OF ONCOLOGY
- Safety and efficacy of the addition of simvastatin to panitumumab in previously treated KRAS mutant metastatic colorectal cancer patients
- (2015) Jara M. Baas et al. ANTI-CANCER DRUGS
- Ibrutinib : applications cliniques et perspectives de développement dans les hémopathies malignes B
- (2015) Catherine Thieblemont BULLETIN DU CANCER
- Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer
- (2015) K. S. Tewari et al. CLINICAL CANCER RESEARCH
- FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
- (2015) G. Kim et al. CLINICAL CANCER RESEARCH
- ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer
- (2015) R. Govindan et al. CLINICAL CANCER RESEARCH
- Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer
- (2015) M. Peeters et al. CLINICAL CANCER RESEARCH
- Lung Master Protocol (Lung-MAP)--A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400
- (2015) R. S. Herbst et al. CLINICAL CANCER RESEARCH
- FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
- (2015) S. Khozin et al. CLINICAL CANCER RESEARCH
- Innovative Clinical Trials: The LUNG-MAP Study
- (2015) CE Steuer et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer
- (2015) DE Gerber et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
- (2015) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- NCI-MATCH Launch Highlights New Trial Design in Precision-Medicine Era:
- (2015) Caroline McNeil JNCI-Journal of the National Cancer Institute
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- Precision medicine: lessons learned from the SHIVA trial
- (2015) Apostolia M Tsimberidou et al. LANCET ONCOLOGY
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
- (2015) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
- (2015) Christophe Le Tourneau et al. LANCET ONCOLOGY
- Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial
- (2015) Jean Jacques Grob et al. LANCET ONCOLOGY
- The Brave New World of clinical cancer research: Adaptive biomarker-driven trials integrating clinical practice with clinical research
- (2015) Donald A. Berry Molecular Oncology
- Patient-centric trials for therapeutic development in precision oncology
- (2015) Andrew V. Biankin et al. NATURE
- NCI-MATCH pairs tumor mutations with matching drugs
- (2015) Vicki Brower NATURE BIOTECHNOLOGY
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- (2015) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- NCI-MATCH Launch Highlights New Trial Design in Precision-Medicine Era:
- (2015) Caroline McNeil JNCI-Journal of the National Cancer Institute
- Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance
- (2015) Zilan Song et al. Acta Pharmaceutica Sinica B
- Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia
- (2014) Carlo Gambacorti-Passerini et al. AMERICAN JOURNAL OF HEMATOLOGY
- Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor
- (2014) J. K. Won et al. ANNALS OF ONCOLOGY
- I-SPY2 trial yields first results on combination therapy for triple-negative breast cancer
- (2014) Carrie Printz CANCER
- A Single-Arm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma in the United States
- (2014) Lawrence Flaherty et al. CANCER JOURNAL
- U.S. Food and Drug Administration Approval: Crizotinib for Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer That Is Anaplastic Lymphoma Kinase Positive
- (2014) S. M. Malik et al. CLINICAL CANCER RESEARCH
- FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
- (2014) L. Amiri-Kordestani et al. CLINICAL CANCER RESEARCH
- Ibrutinib: First Global Approval
- (2014) Fiona Cameron et al. DRUGS
- PARP inhibitors in ovarian cancer: Current status and future promise
- (2014) Joyce F. Liu et al. GYNECOLOGIC ONCOLOGY
- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
- (2014) Mark G. Kris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients WithBRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor
- (2014) Douglas B. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study
- (2014) Antoni Ribas et al. LANCET ONCOLOGY
- Clinical development success rates for investigational drugs
- (2014) Michael Hay et al. NATURE BIOTECHNOLOGY
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Crizotinib for the Treatment of Metastatic Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements
- (2014) D. Kazandjian et al. ONCOLOGIST
- Molecular Analysis for Therapy Choice: NCI MATCH
- (2014) Barbara A. Conley et al. SEMINARS IN ONCOLOGY
- NCI Launches ALCHEMIST
- (2014) Cancer Discovery
- Ado-trastuzumab emtansine approved for advanced breast cancer
- (2013) K. Traynor AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- ROS1 Immunohistochemistry for Detection of ROS1-Rearranged Lung Adenocarcinomas
- (2013) Lynette M. Sholl et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Adaptive enrichment designs for clinical trials
- (2013) N. Simon et al. BIOSTATISTICS
- A Critical Review of Trials of First-Line BCR-ABL Inhibitor Treatment in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
- (2013) Elias Jabbour et al. Clinical Lymphoma Myeloma & Leukemia
- Designing Transformative Clinical Trials in the Cancer Genome Era
- (2013) Stefan Sleijfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
- (2013) Paolo A. Ascierto et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarker enrichment strategies: matching trial design to biomarker credentials
- (2013) Boris Freidlin et al. Nature Reviews Clinical Oncology
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
- (2013) J.E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Approval Summary: Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil for the First-Line Treatment of Patients With Recurrent Locoregional or Metastatic Squamous Cell Head and Neck Cancer
- (2013) M. H. Cohen et al. ONCOLOGIST
- Comparison of Testing Methods for the Detection of BRAF V600E Mutations in Malignant Melanoma: Pre-Approval Validation Study of the Companion Diagnostic Test for Vemurafenib
- (2013) Fernando Lopez-Rios et al. PLoS One
- Targeted therapies in medical oncology: successes, failures and next steps
- (2013) Gordon Mallarkey et al. Therapeutic Advances in Medical Oncology
- Food and Drug Administration Approval of Cetuximab and a New KRAS Genetic Test for Metastatic Colorectal Cancer
- (2012) Ronald Lieberman AMERICAN JOURNAL OF THERAPEUTICS
- Reports from the 2010 Clinical and Translational Cancer Research Think Tank Meeting: Design Strategies for Personalized Therapy Trials
- (2012) D. A. Berry et al. CLINICAL CANCER RESEARCH
- Cost Analysis of Erlotinib Versus Chemotherapy for First-Line Treatment of Non–Small-Cell Lung Cancer in Frail Elderly Patients Participating in a Prospective Phase 2 Study (GFPC 0505)
- (2012) Christos Chouaid et al. Clinical Lung Cancer
- Vemurafenib in Patients With BRAF V600E Mutation–Positive Advanced Melanoma
- (2012) Marcus C. Ravnan et al. CLINICAL THERAPEUTICS
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- (2012) Kristin Bergethon et al. JOURNAL OF CLINICAL ONCOLOGY
- Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial
- (2012) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
- (2012) José Baselga et al. LANCET
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
- (2012) Vincent A Miller et al. LANCET ONCOLOGY
- Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
- (2012) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- (2012) Georgina V Long et al. LANCET ONCOLOGY
- Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
- (2012) Jorge E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost Effectiveness of Personalized Therapy for First-Line Treatment of Stage IV and Recurrent Incurable Adenocarcinoma of the Lung
- (2012) Elizabeth A. Handorf et al. Journal of Oncology Practice
- Rituximab in chronic lymphocytic leukemia
- (2011) Danelle F. James et al. ADVANCES IN THERAPY
- New melanoma drug requires gene mutation test
- (2011) C. A. Thompson AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Vemurafenib (PLX4032): An Orally Available Inhibitor of Mutated BRAF for the Treatment of Metastatic Melanoma
- (2011) Yasser Heakal et al. ANNALS OF PHARMACOTHERAPY
- CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
- (2011) Hiroshi Sakamoto et al. CANCER CELL
- Fulvestrant Revisited: Efficacy and Safety of the 500-mg Dose
- (2011) Anthony Howell et al. Clinical Breast Cancer
- Cetuximab in the treatment of patients with colorectal cancer
- (2011) Christopher R Garrett et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer
- (2011) Sarah M Scott et al. Expert Opinion On Drug Safety
- The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer
- (2011) Giulio Metro et al. Expert Review of Anticancer Therapy
- Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
- (2011) Masahiro Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
- (2011) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- The BATTLE Trial: A Bold Step toward Improving the Efficiency of Biomarker-Based Drug Development
- (2011) Eric H. Rubin et al. Cancer Discovery
- The BATTLE Trial: Personalizing Therapy for Lung Cancer
- (2011) Edward S. Kim et al. Cancer Discovery
- BATTLE to personalize lung cancer treatment
- (2010) Carrie Printz CANCER
- Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial
- (2010) Binghe Xu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study
- (2010) Marinus H.J. van Oers et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Clinical Trials With Biomarkers: Design Issues
- (2010) B. Freidlin et al. JNCI-Journal of the National Cancer Institute
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Adaptive BATTLE trial uses biomarkers to guide lung cancer treatment
- (2010) NATURE REVIEWS DRUG DISCOVERY
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
- (2010) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fulvestrant: Expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer
- (2008) Stephen Chia et al. BREAST
- A History of Cancer Chemotherapy
- (2008) Vincent T. DeVita et al. CANCER RESEARCH
- Randomized Phase III Clinical Trial Designs for Targeted Agents
- (2008) A. Hoering et al. CLINICAL CANCER RESEARCH
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
- (2008) Edward S Kim et al. LANCET
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
- The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Non–Small-Cell Lung Cancer
- (2008) Josh J. Carlson et al. VALUE IN HEALTH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now